Supernus Pharmaceuticals (SUPN) Financials
$42.07
As on 09-Sep-2026 16:00EDT
Market cap
$2,530 Mln
Revenue (TTM)
$830 Mln
P/E Ratio
--
P/B Ratio
2.5
Div. Yield
0 %
Income Statement ($ Mln) |
TTM | Dec-25 | Dec-24 | Dec-23 | Dec-22 | Dec-21 | Dec-20 | Dec-19 | Dec-18 | Dec-17 | Dec-16 |
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Operating Revenue
|
830.44
|
718.95
|
661.82
|
607.52
|
667.24
|
579.78
|
|||||
|
Cost of Revenue
|
99.03
|
74.56
|
77.91
|
83.78
|
87.22
|
75.06
|
|||||
|
Gross Profit
|
731.41
|
644.39
|
583.91
|
523.74
|
580.02
|
504.71
|
|||||
|
Operating Expenses
|
844.11
|
681.25
|
502.25
|
529.01
|
533.89
|
418.69
|
|||||
|
Operating Profit (EBIT)
|
-111.81
|
-36.86
|
81.67
|
-5.27
|
46.12
|
86.03
|
|||||
|
Other Income
|
--
|
--
|
--
|
--
|
14.62
|
-12.85
|
|||||
|
Profit before Tax
|
-123.47
|
-49.03
|
97.87
|
2.77
|
60.74
|
73.18
|
|||||
|
Provision for Tax
|
-13.58
|
-10.48
|
24.01
|
1.45
|
0.03
|
19.75
|
|||||
|
Profit after Tax (Net Income)
|
-109.89
|
-38.55
|
73.87
|
1.32
|
60.71
|
53.42
|
|||||
|
Minority Interest
|
--
|
--
|
--
|
--
|
--
|
--
|
|||||
|
Consolidated Profit
|
--
|
--
|
--
|
--
|
60.71
|
53.42
|
Liabilities ($ Mln) |
TTM | Dec-25 | Dec-24 | Dec-23 | Dec-22 | Dec-21 | Dec-20 | Dec-19 | Dec-18 | Dec-17 | Dec-16 |
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Shareholder's Funds
|
1,031.23
|
1,061.71
|
1,035.73
|
921.52
|
886.20
|
815.85
|
|||||
|
Minority Interest
|
--
|
--
|
--
|
--
|
--
|
--
|
|||||
|
Non-Current Liabilities
|
49.50
|
52.76
|
39.94
|
65.96
|
128.35
|
557.92
|
|||||
|
Current Liabilities
|
347.38
|
338.17
|
292.40
|
290.20
|
687.96
|
315.38
|
|||||
|
Total Liabilities
|
1,775.49
|
1,452.65
|
1,368.07
|
1,277.67
|
1,702.51
|
1,689.15
|
Assets ($ Mln) |
TTM | Dec-25 | Dec-24 | Dec-23 | Dec-22 | Dec-21 | Dec-20 | Dec-19 | Dec-18 | Dec-17 | Dec-16 |
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Non-Current Assets
|
704.61
|
808.47
|
682.00
|
784.56
|
968.36
|
1,087.56
|
|||||
|
Current Assets
|
723.50
|
644.18
|
686.07
|
493.11
|
734.15
|
601.59
|
|||||
|
Total Assets
|
1,775.49
|
1,452.65
|
1,368.07
|
1,277.67
|
1,702.51
|
1,689.15
|
|||||
|
Total Debt*
|
40.17
|
40.98
|
34.27
|
41.53
|
444.76
|
427.03
|
|||||
|
Net Current Assets
|
376.12
|
306.01
|
393.67
|
202.92
|
46.19
|
286.21
|
Cashflow ($ Mln) |
TTM | Dec-25 | Dec-24 | Dec-23 | Dec-22 | Dec-21 | Dec-20 | Dec-19 | Dec-18 | Dec-17 | Dec-16 |
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Cash From Operating Activities
|
--
|
47.33
|
171.95
|
111.09
|
116.83
|
127.13
|
|||||
|
Cash Flow from Investing Activities
|
--
|
4.11
|
-189.87
|
268.73
|
-216.66
|
-81.91
|
|||||
|
Cash from Financing Activities
|
--
|
9.13
|
12.19
|
-397.88
|
-10.48
|
-130.42
|
|||||
|
Net Cash Inflow / Outflow
|
--
|
--
|
--
|
--
|
-110.31
|
-85.21
|
Financials Ratios |
TTM | Dec-25 | Dec-24 | Dec-23 | Dec-22 | Dec-21 | Dec-20 | Dec-19 | Dec-18 | Dec-17 | Dec-16 |
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Adjusted EPS ($)
|
-1.91
|
-0.67
|
1.31
|
0.02
|
0.98
|
1.00
|
|||||
|
Cash EPS ($)
|
--
|
0.92
|
2.73
|
1.55
|
2.31
|
1.62
|
|||||
|
Adjusted Book Value ($)
|
--
|
18.51
|
18.34
|
16.74
|
14.27
|
15.32
|
|||||
|
Dividend per Share ($)
|
--
|
--
|
--
|
--
|
--
|
--
|
|||||
|
Cash Flow per Share ($)
|
--
|
0.83
|
3.05
|
2.02
|
1.88
|
2.39
|
|||||
|
Free Cash Flow per Share ($)
|
--
|
0.80
|
3.03
|
2.01
|
1.87
|
2.35
|
Profitability Ratios |
TTM | Dec-25 | Dec-24 | Dec-23 | Dec-22 | Dec-21 | Dec-20 | Dec-19 | Dec-18 | Dec-17 | Dec-16 |
|---|---|---|---|---|---|---|---|---|---|---|---|
|
ROCE (%)
|
--
|
-3.55
|
7.27
|
0.11
|
4.72
|
4.45
|
|||||
|
ROE (%)
|
-10.50
|
-3.68
|
7.55
|
0.15
|
7.13
|
6.85
|
|||||
|
ROA (%)
|
-6.38
|
-2.73
|
5.58
|
0.09
|
3.58
|
3.35
|
|||||
|
EBIT Margin (%)
|
-14.16
|
-6.82
|
14.79
|
0.85
|
10.16
|
16.66
|
|||||
|
Net Margin (%)
|
-13.23
|
-5.36
|
11.16
|
0.22
|
8.90
|
9.42
|
|||||
|
Cash Profit Margin (%)
|
--
|
--
|
--
|
--
|
--
|
--
|
Growth Ratios |
TTM | Dec-25 | Dec-24 | Dec-23 | Dec-22 | Dec-21 | Dec-20 | Dec-19 | Dec-18 | Dec-17 | Dec-16 |
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Revenue Growth (%)
|
24.85
|
0.09
|
0.09
|
-0.09
|
0.15
|
0.11
|
|||||
|
EBIT Growth (%)
|
-237.69
|
-150.10
|
1,787.92
|
-92.36
|
-29.80
|
-49.79
|
|||||
|
Net Profit Growth (%)
|
-270.37
|
-152.19
|
5,512.84
|
-97.83
|
13.64
|
-57.92
|
|||||
|
EPS Growth (%)
|
-267.31
|
-1.51
|
53.73
|
-0.98
|
-0.03
|
-0.58
|
|||||
|
Book Value Growth (%)
|
-5.45
|
--
|
--
|
--
|
--
|
--
|
Valuation Ratios |
TTM | Dec-25 | Dec-24 | Dec-23 | Dec-22 | Dec-21 | Dec-20 | Dec-19 | Dec-18 | Dec-17 | Dec-16 |
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Price / Earnings
|
--
|
-73.93
|
27.64
|
1,210.77
|
36.48
|
29.07
|
|||||
|
Price / Book Value
|
2.48
|
2.68
|
1.97
|
1.73
|
2.50
|
1.90
|
|||||
|
Dividend Yield (%)
|
--
|
--
|
--
|
--
|
--
|
--
|
|||||
|
EV/EBITDA
|
51.86
|
60.71
|
9.10
|
15.33
|
14.33
|
12.70
|
|||||
|
Close Price ($)
|
46.51
|
49.70
|
36.16
|
28.94
|
35.67
|
29.16
|
|||||
|
High Price ($)
|
59.68
|
57.65
|
39.37
|
42.09
|
38.40
|
34.50
|
|||||
|
Low Price ($)
|
31.35
|
29.16
|
25.53
|
21.99
|
24.95
|
23.15
|
|||||
|
Market Cap ($ Cr)
|
2,530.27
|
--
|
--
|
--
|
--
|
--
|
Solvency Ratios |
TTM | Dec-25 | Dec-24 | Dec-23 | Dec-22 | Dec-21 | Dec-20 | Dec-19 | Dec-18 | Dec-17 | Dec-16 |
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Debt to Equity
|
--
|
0.04
|
0.03
|
0.05
|
0.50
|
0.52
|
|||||
|
Short term debt to equity ratio
|
0.01
|
0.01
|
0.01
|
0.01
|
0.46
|
0.01
|
|||||
|
Current Ratio
|
2.08
|
1.90
|
2.35
|
1.70
|
1.07
|
1.91
|
|||||
|
Quick Ratio
|
1.84
|
1.66
|
2.16
|
1.43
|
0.93
|
1.63
|
|||||
|
Interest Coverage
|
-52.33
|
--
|
--
|
2.15
|
9.59
|
4.12
|
Operating Efficiency Ratios |
TTM | Dec-25 | Dec-24 | Dec-23 | Dec-22 | Dec-21 | Dec-20 | Dec-19 | Dec-18 | Dec-17 | Dec-16 |
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Debtors to sales (%)
|
25.49
|
26.12
|
21.47
|
23.73
|
24.80
|
25.69
|
|||||
|
Asset Turnover
|
0.48
|
0.51
|
0.50
|
0.41
|
0.39
|
0.36
|
|||||
|
Receivable days
|
--
|
83.79
|
78.98
|
93.08
|
86.06
|
91.29
|
|||||
|
Inventory Days
|
--
|
334.77
|
308.73
|
368.28
|
371.65
|
326.72
|
|||||
|
Payable days
|
--
|
17.79
|
15.36
|
27.26
|
41.61
|
37.66
|
|||||
|
Cash Conversion Cycle
|
--
|
400.77
|
372.36
|
434.10
|
416.10
|
380.35
|